Tolerance and safety of enalapril.
Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension.
D002216:Captopril / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology; D004656:Enalapril; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007958:Leukocyte Count; D011507:Proteinuria / Q000139:chemically induced; D013649:Taste / Q000187:drug effects; D014511:Uremia / Q000139:chemically induced
D004151:Dipeptides; D004791:Enzyme Inhibitors; D004656:Enalapril; D002216:Captopril